Sara Routsi advises clients on all aspects of European and international competition law, including abuse of dominance, cartels, antitrust compliance, and multijurisdictional merger control filings. Her experience covers a diverse range of industry sectors, including medical devices, pharmaceuticals, technology, automotive, and banking.
Prior to joining Arnold & Porter in 2022, Sara worked as trainee at the Directorate General for Competition of the European Commission where she focused on the assessment of mergers in the sectors of basic industries and manufacturing. She also worked as a trainee at the Hellenic Competition Commission, where she assisted in art.101 and 102 TFEU cases in the sectors of consumer products, construction and financial services. Her previous work experience also includes advising on various aspects of Greek banking and corporate law.
Experience
- Novo Nordisk on European and other international antitrust and regulatory approvals in connection with its US$11 billion acquisition of three fill-finish sites from Novo Holdings A/S (Novo Holdings). As part of the deal, valued at US$16.5 billion, Novo Holdings will acquire (through a merger) Catalent, Inc., a NYSE listed CDMO headquartered in New Jersey.
- Novo Nordisk in its acquisition of Cardior Pharmaceuticals for up to EUR€1.025 billion, including upfront payment and additional milestones, to secure merger control and regulatory approvals.
- Novo Nordisk in its acquisition of Inversago Pharma for up to US$1.075 billion including milestones, to secure merger control and regulatory approvals.
- Novo Nordisk in its acquisition of Biocorp, to secure merger control and regulatory approvals.
- Boston Scientific in its US$615 million acquisition of Apollo Endosurgery.
Perspectives
Credentials
Education
- LL.M., International and European Law, University of Amsterdam, 2021, cum laude
- LL.B., Law, National and Kapodistrian University of Athens School of Law, 2019
Admissions
- Brussels, Belgium
- Athens, Greece